Telix Pharmaceuticals (ASX:TLX) filed a biological license application for its kidney cancer imaging agent Zircaix, or TLX250-CDx, with the US Food and Drug Administration, according to a Monday filing with the Australian bourse.

The agent is an investigational positron emission tomography product used to detect clear cell renal carcinoma, a form of kidney cancer, on a non-invasive basis, the filing said.

The company's shares were down almost 2% in recent Monday trade.